| __timestamp | Catalyst Pharmaceuticals, Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 10117774 | 347523000 |
| Thursday, January 1, 2015 | 11801342 | 479514000 |
| Friday, January 1, 2016 | 11369941 | 581861000 |
| Sunday, January 1, 2017 | 11375237 | 1326361000 |
| Monday, January 1, 2018 | 19919204 | 1197957000 |
| Tuesday, January 1, 2019 | 18842752 | 1154111000 |
| Wednesday, January 1, 2020 | 16496715 | 2215942000 |
| Friday, January 1, 2021 | 16936000 | 1458179000 |
| Saturday, January 1, 2022 | 19789000 | 1585936000 |
| Sunday, January 1, 2023 | 93150000 | 1627594000 |
| Monday, January 1, 2024 | 2606848000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Incyte Corporation and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Incyte Corporation consistently outpaced Catalyst Pharmaceuticals, with R&D expenses peaking at approximately $1.63 billion in 2023, a staggering 1,600% increase compared to Catalyst's $93 million in the same year. This trend highlights Incyte's aggressive strategy to maintain its competitive edge in the biotech sector. Meanwhile, Catalyst Pharmaceuticals has shown a more conservative growth in R&D spending, with a notable surge in 2023, marking a 370% increase from its 2014 levels. As these companies continue to innovate, their R&D investments will likely play a pivotal role in shaping their future success.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Catalyst Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. or Catalyst Pharmaceuticals, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Biogen Inc. and Incyte Corporation
Analyzing R&D Budgets: BeiGene, Ltd. vs Catalyst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Incyte Corporation and Lantheus Holdings, Inc.
Incyte Corporation vs Perrigo Company plc: Strategic Focus on R&D Spending
Incyte Corporation vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Incyte Corporation vs Mesoblast Limited: Strategic Focus on R&D Spending
Comparing Innovation Spending: Incyte Corporation and Iovance Biotherapeutics, Inc.
Analyzing R&D Budgets: Summit Therapeutics Inc. vs Catalyst Pharmaceuticals, Inc.
ADMA Biologics, Inc. vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Catalyst Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.